Halozyme
HALO
636 hedge funds and large institutions have $7.79B invested in Halozyme in 2026 Q1 according to their latest regulatory filings, with 98 funds opening new positions, 235 increasing their positions, 214 reducing their positions, and 70 closing their positions.
40% more first-time investments, than exits
New positions opened: 98 | Existing positions closed: 70
39% more call options, than puts
Call options by funds: $24.6M | Put options by funds: $17.7M
3% more funds holding
Funds holding: 618 → 636 (+18)
10% more repeat investments, than reductions
Existing positions increased: 235 | Existing positions reduced: 214
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
3.1% less ownership
Funds ownership: 104.77% → 101.67% (-3.1%)
6% less capital invested
Capital invested by funds: $8.29B → $7.79B (-$504M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$155M |
| 2 |
Two Sigma Investments
New York
|
+$61.2M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
+$48.1M |
| 4 |
Jane Street
New York
|
+$47M |
| 5 |
EIP
Epoch Investment Partners
New York
|
+$42.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$92M |
| 2 |
Millennium Management
New York
|
-$70M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$45.2M |
| 4 |
N
Natixis
Paris,
France
|
-$32.9M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$31.8M |
HALO Hedge Fund Activity: Q1 2026 in Review
636 of the 8,186 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q1 2026, worth a combined $7.79B — down 6.1% from $8.29B a quarter earlier.
Buyers outnumbered sellers: 98 funds opened new HALO positions and 70 closed out — a net gain of 28 holders — while 235 added to existing stakes and 214 trimmed.
The largest buyer was Boston Partners, adding an estimated $155M. The largest seller was Arrowstreet Capital, cutting an estimated $92M.
- 636 institutional investors held Halozyme (HALO) as of Q1 2026, up from 618 in Q4 2025.
- Funds reported $7.79B of Halozyme stock for Q1 2026, down 6.1% quarter-over-quarter.
- 98 funds opened new Halozyme positions in Q1 2026 and 70 closed out, a net change of +28 holders.
- The largest Halozyme buyer in Q1 2026 was Boston Partners, an estimated $155M added.
- The largest Halozyme seller in Q1 2026 was Arrowstreet Capital, an estimated $92M sold.
Based on aggregated 13F filings for Q1 2026.